Jinyu Bio-technology Co., Ltd. was founded in March 1993, with a registered capital of 572829860. Then it was listed at Shanghai Stock Exchange in January 1999, stock code: 600201.
By the end of September 2013, the Group kept a total capital of 1.78 billion Yuan and 983 staffs, ranking as a blue-chip listed company in the Biopharmaceutical Block of A-share.
Jinyu Group adheres to the enterprise vision of “Commit to Healthy Cause ,Co-create for A Better Life”, complies with the core value of “Gold Centers on Human and Large Swans Soar even in the Vast Sky” and continually carries out innovation on management, technology and product, improving its core competitiveness constantly.
The Spirit Jinyu Biological Pharmaceutical Co., LTD and Yangzhou Uni-Bio Pharmaceutical Co., LTD subordinated are both state-level high and new technology enterprises.
The Spirit Jinyu Biological Pharmaceutical Co., LTD is a Vice-director Unit in China Animal Protection Association, owning the only Veterinary Vaccine National Engineering Lab;
In 2008, as the first one that solved the technical problem of cell suspension culture, it launched the first production line of suspension culture for FMD vaccine in the country, which filled a domestic gap in this field and led the upgrade in the industry;
In 2012, it developed three standards for the vaccine of FMD: Antigen Content, Impure Protein Content, Antigen and Impure Protein Detection.
Jinyu Bio-Technology Industrial Park is planning to build production lines with high standard for FMD suspension culture and brucellosis vaccine, as well as a National High-Level Biosesafety Lab, by which it will take the historical mission to promote the innovation of product and technology in domestic bio-pharmaceutical industry.